N. Brendish

发表

Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol

Ahalya K. Malachira, T. Clark, Kate R. Beard, 2019, BMJ Open.

Combined RT-PCR and Host Response Point-of-Care Testing in Patients Hospitalised with Suspected COVID-19: A Prospective Diagnostic Accuracy Study

T. Clark, L. Presland, Vasanth V. Naidu, 2022, Infectious Diseases and Therapy.

Respiratory tract infection associated with seizures

S. Faust, M. Tebruegge, N. Brendish, 2015, BMJ : British Medical Journal.

Treatment of influenza with neuraminidase inhibitors

T. Clark, Kate R. Beard, N. Brendish, 2018, Current opinion in infectious diseases.

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

J. Vekemans, S. Faust, A. Lawrie, 2021, Frontiers in Immunology.

Neuraminidase inhibitor use in adults presenting to hospital with suspected influenza: A questionnaire-based survey of practice among hospital physicians

Ahalya K. Malachira, T. Clark, P. Lillie, 2021, Clinical Infection in Practice.

Antiviral treatment of severe non-influenza respiratory virus infection

T. Clark, N. Brendish, 2017, Current opinion in infectious diseases.

Evaluating the Immune Response in Treatment-Naive Hospitalised Patients With Influenza and COVID-19

D. Baralle, James P R Schofield, Fabio Strazzeri, 2022, Frontiers in Immunology.

Impact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease

S. Ewings, T. Clark, N. Brendish, 2019, Journal of Infection.

Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine

R. Read, N. Brendish, 2015, Expert review of vaccines.

Blood gene expression predicts intensive care unit admission in hospitalised patients with COVID-19

D. Baralle, James P R Schofield, Fabio Strazzeri, 2022, Frontiers in Immunology.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Juliana K. Wambua, J. McCarthy, J. Vekemans, 2017, JCI insight.

Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study

S. Ewings, F. Borca, S. Kidd, 2020, The Lancet Respiratory Medicine.

Temporal analysis of early immune responses in patients with acute hepatitis B virus infection.

P. Klenerman, M. Maini, G. Dusheiko, 2009, Gastroenterology.

Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus

T. Clark, N. Brendish, S. Poole, 2020, The Lancet Respiratory Medicine.

SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study

T. Clark, N. Brendish, S. Poole, 2020, Journal of Infection.

Distinct immune responses in patients infected with influenza or SARS-CoV-2, and in COVID-19 survivors, characterised by transcriptomic and cellular abundance differences in blood.

D. Baralle, Fabio Strazzeri, P. Skipp, 2021, medRxiv.

Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial

S. Ewings, Ahalya K. Malachira, T. Clark, 2017, The Lancet Respiratory Medicine.

Point-of-care testing for respiratory viruses in adults: The current landscape and future potential

Tristan W. Clark, H. Schiff, T. Clark, 2015, Journal of Infection.

Inflammatory phenotyping predicts clinical outcome in COVID-19

James Batchelor, C. Kipps, F. Borca, 2020, Respiratory Research.

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

G. Alter, M. White, S. Faust, 2021, Med.

FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department

R. Crouch, F. Borca, M. Kiuber, 2022, Infection Control & Hospital Epidemiology.

Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19

Tristan W. Clark, Sean Ewings, S. Ewings, 2020, Journal of Infection.

Hospitalised adults with pneumonia are frequently misclassified as another diagnosis.

Ahalya K. Malachira, T. Clark, P. Lillie, 2019, Respiratory medicine.

Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection

F. Borca, T. Clark, L. Presland, 2020, Journal of Infection.

Influenza vaccination: protecting the most vulnerable

R. Dorey, T. Clark, N. Brendish, 2021, European Respiratory Review.

Molecular point-of-care testing for respiratory viruses versus routine clinical care in adults with acute respiratory illness presenting to secondary care: a pragmatic randomised controlled trial protocol (ResPOC)

Ahalya K. Malachira, T. Clark, N. Brendish, 2017, BMC Infectious Diseases.

Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial

S. Ewings, Ahalya K. Malachira, T. Clark, 2020, The Lancet. Respiratory medicine.

A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries

R. Eason, C. Sones, O. Quaye, 2021, Journal of Infection.

Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial

S. Ewings, Ahalya K. Malachira, T. Clark, 2018, European Respiratory Journal.

Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: A prospective, interventional, non-randomised pre and post implementation study (CoV-19POC) [Protocol]

T. Clark, N. Brendish, 2020 .

Re: 'Syndromic panels or “panel syndrome”? A perspective through the lens of respiratory-tract infections' by Zanella et al

T. Clark, N. Brendish, S. Poole, 2020, Clinical Microbiology and Infection.

Molecular Point-of-care Testing for Influenza to Improve Early Neuraminidase Inhibitor Treatment and Outcomes in Hospitalized Adults.

T. Clark, N. Brendish, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT

J. Baum, A. Blagborough, S. Faust, 2017 .

SARS-CoV-2 viral load at presentation to hospital is independently associated with the risk of death

F. Borca, H. Phan, Kate R. Beard, 2021, Journal of Infection.

Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): a pragmatic, open-label, randomised controlled trial.

Ahalya K. Malachira, T. Clark, H. Moyses, 2023, The Lancet. Infectious diseases.

Routine molecular point-of-care testing for SARS-CoV-2 reduces hospital-acquired COVID-19

F. Borca, T. Clark, H. Lin, 2022, Journal of Infection.

Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19

M. G. Jones, B. Marshall, T. Clark, 2021, Respiratory Research.

Global extent of chloroquine-resistant Plasmodium vivax.

N. Brendish, 2015, The Lancet. Infectious diseases.

Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.

F. Borca, N. Brendish, Daniel Waddington, 2023, The Journal of infection.

Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial

S. Ewings, Ahalya K. Malachira, T. Clark, 2017, The Lancet Respiratory Medicine.